Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991224 | 0.98 | SMN1; SMN2 (0.44) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL4325752 | 0.98 | SMN1; SMN2 (0.44) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL7991219 | 0.98 | SMN1; SMN2 (0.44) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL791252 | 0.94 | ALDH1A1 (0.43) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL7485263 | 0.93 | — | — | |
| SCHEMBL4337065 | 0.92 | SMN1; SMN2 (0.42) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL4325783 | 0.92 | ALDH1A1 (0.42) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL4953807 | 0.92 | ALDH1A1 (0.42) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL4337073 | 0.92 | SMN1; SMN2 (0.42) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 | |
| SCHEMBL7485551 | 0.87 | ALDH1A1 (0.37) | ALDH1A1ALOX15SMN1; SMN2USP2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | claimed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | claimed |
| WO-2024106539-A1 | LIGAND CONJUGATE SUBSTANCE, NUCLEIC ACID CONTAINING SAME, AND USE THEREOF | 株式会社ボナック | 2024-05-23 | — | — | WO | disclosed |
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-4206325-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-3527578-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | Bonac Corporation (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-10377788-B2 | Method for producing glycoside compounds | BONAC CORPORATION (JP) | 2019-08-13 | — | — | US | disclosed |
| EP-3301103-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9222032-B2 | Composition and methods for improved fuel production | MISSISSIPPI STATE UNIVERSITY (US) | 2015-12-29 | — | — | US | disclosed |
| EP-0742218-A1 | PYRROLOPYRIDAZINE DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0227241-A2 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC. (US) | 1987-07-01 | — | — | EP | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4333940-A | Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development | AMERICAN CYANAMID COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
| US-4243609-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | ALDH1A1 3438/4885ALOX15 4629/4885SMN1; SMN2 2121/4885 |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | SLC5A11, POLRMT, MAPK11 | ALDH1A1 3258/4885ALOX15 2485/4885SMN1; SMN2 2393/4885 |
| US-10377788-B2 | Method for producing glycoside compounds | TST, DIMT1, DERA | ALDH1A1 808/4885ALOX15 2636/4885SMN1; SMN2 3768/4885 |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | TST, DIMT1, DERA | ALDH1A1 808/4885ALOX15 2636/4885SMN1; SMN2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.